Mismatch repair (MMR) proteins (MLH1, PMS2, MSH2 and MSH6) immunohistochemistry is a collective qualitative assay to identify patients eligible for treatment with JEMPERLI® (dostarlimab-gxly) or KEYTRUDA® (pembrolizumab) in MMR deficient (dMMR) solid tumours including endometrial carcinoma, and a combination of KEYTRUDA (pembrolizumab) and LENVIMA (lenvatinib) in MMR proficient (pMMR) endometrial carcinoma.
Therapy and associated indication:
